Celldex Therapeutics (CLDX) Expected to Announce Earnings on Thursday

Celldex Therapeutics (NASDAQ:CLDX) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.00) per share and revenue of $1.5330 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, February 23, 2026 at 4:00 PM ET.

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock opened at $23.00 on Thursday. Celldex Therapeutics has a 1 year low of $14.40 and a 1 year high of $30.50. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -6.80 and a beta of 1.24. The company has a 50-day moving average of $25.68 and a 200 day moving average of $25.26.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on CLDX shares. Barclays lifted their target price on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.56.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CLDX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Celldex Therapeutics by 1.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after purchasing an additional 680 shares in the last quarter. Millennium Management LLC grew its stake in shares of Celldex Therapeutics by 327.3% during the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock valued at $7,259,000 after acquiring an additional 306,330 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Celldex Therapeutics by 12.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock worth $2,383,000 after acquiring an additional 14,979 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 501 shares during the period. Finally, Hsbc Holdings PLC purchased a new position in Celldex Therapeutics during the second quarter valued at approximately $347,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.